Cytotoxic and targeted therapy for hereditary cancers

There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitom...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyevleva, Aglaya G., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994296/
https://www.ncbi.nlm.nih.gov/pubmed/27555886
http://dx.doi.org/10.1186/s13053-016-0057-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994296/
https://www.ncbi.nlm.nih.gov/pubmed/27555886
http://dx.doi.org/10.1186/s13053-016-0057-2

Ejemplares similares